ANI Launches ~$560M Cash Offer for Egetis, Backed by $676M JPMorgan Bridge Facility
ANIP is trading near its 52-week low of $68.785 (0.3% above the low) on elevated volume (3.1× avg).
Summary
ANI agreed to acquire Egetis for about $560 million in cash, funded with cash on hand and a new $676 million JPMorgan bridge facility. The offer carries a 12.6% premium to Egetis' last close and needs over 90% acceptance plus regulatory clearances.
Key Events · M&A and Partnerships · ANIP
-
Recommended Cash Offer for Egetis
ANI is offering SEK 11.25 per Egetis share, SEK 65,750,817 for the EUR 3 million convertible and SEK 6.99 per warrant, for total value of approximately SEK 5.6 billion (~$559.9 million) at a 9.9471 USD/SEK rate.
-
Premium to Recent Trading
The SEK 11.25 price is a 12.6% premium to the SEK 9.99 close on November 4, 2026, 27.0% to the 60-day VWAP of SEK 8.86 and 48.0% to the 180-day VWAP of SEK 7.60.
-
$676M Bridge Facility Signed
The 364-day senior bridge from JPMorgan Chase prices at ABR plus 1.75% or adjusted term SOFR plus 2.75%, with margins rising 0.25% at 90, 180 and 270 days after funding; it is initially unsecured and becomes secured by substantially all assets when drawn.
-
42.2% Already Committed to Tender
Irrevocable undertakings cover 196,127,092 Egetis shares (~42.2%), including Frazier Life Sciences at ~16.65%, but completion still requires more than 90% acceptance on a fully diluted basis plus competition and FDI clearances.
Analysis · ANIP · Life Sciences
ANI is committing roughly $560 million of cash to buy Swedish rare-disease company Egetis, funded by cash on hand plus a new $676 million 364-day bridge from JPMorgan. The bridge starts unsecured but becomes secured by substantially all of ANI's assets once drawn, and it also refinances ANI's existing term loans. That is a large, short-dated debt load taken on to secure EMCITATE, the only approved MCT8 deficiency treatment, which ANI pegs at over $300 million of peak sales with protection into 2045. The deal is not done: it needs more than 90% of Egetis shares to tender, plus competition and foreign-investment clearances, with the acceptance period expected to run November 20 to December 18, 2026. Holders of about 42.2% of Egetis shares have already committed to tender, which materially de-risks the 90% threshold but does not guarantee it.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANIP was trading at $69.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $68.79 to $95.57. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.